Advances in Tropheryma whipplei research: the rush to find biomarkers for Whipple''s disease. (December 2007)

• Record Type: Journal Article
• Authors: Kowalczewska, Malgorzata; Raoult, Didier
• Is Part Of: Future microbiology. Volume 2:Number 6(2007)
• Page Start: 631
• Page End: 642
• Publication Date: 2007-12
• Subjects: classical Whipple''s disease -- infective endocarditis -- isolated neurological infection -- monoclonal antibody -- post-translational modifications -- Tropheryma whipplei -- Whipple''s disease; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/17460913.2.6.631
• Languages: English
• ISSNs: 1746-0913

Abstract

Whipple''s disease (WD) is a systemic chronic infection, caused by the Gram-positive bacterium Tropheryma whipplei . There are several clinical traits linked to WD: histological lesions in the GI tract in association with diverse clinical manifestations (classic WD), endocarditis with negative blood cultures, and isolated neurological infection. WD is rare, predominantly affects middle-aged men and is fatal without treatment. The most recent strategy for diagnosing WD uses the results of diastase-resistant periodic acid Schiff staining and PCR in parallel, both performed on involved organ/tissue biopsy (small intestine, cardiac valve and cerebrospinal fluid). The generation of rabbit polyclonal antibodies has enabled the detection of the bacterium in tissues by immunohistochemical staining. However, the diagnosis of WD remains an invasive procedure. The recent achievement of stable bacterial culture and sequencing of the T. whipplei genome has opened a framework for the development of a biomarker platform. Several studies in different fields have been performed, for example, transcriptomics, immunoproteomics and comparative proteomics. Biomarker candidates have been proposed for the development of less invasive procedures for diagnosing WD.